**Tables**

**Table 1: Patient demographics grouped by response to ICI.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Non-Responders (N=45)** | **Responders (N=36)** | **Overall**  **(N=81)** | **P-value** |
| **Age (years)** |  |  |  |  |
| Mean (SD) | 59.4 (17.1) | 68.0 (14.3) | 63.5 (16.3) | 0.0319 |
| Median [Min, Max] | 57.5 [31.0, 87.0] | 73.0 [36.0, 92.0] | 69.0 [31.0, 92.0] |  |
| Missing | 11 (24.4%) | 5 (13.9%) | 16 (19.8%) |  |
| **Prior BRAFi/MEKi therapy** |  |  |  |  |
| No | 15 (33.3%) | 25 (69.4%) | 40 (49.4%) | 0.0081 |
| Yes | 18 (40.0%) | 6 (16.7%) | 24 (29.6%) |  |
| Missing | 12 (26.7%) | 5 (13.9%) | 17 (21.0%) |  |
| **Prior adjuvant IFNγ treatment** |  |  |  |  |
| No | 19 (42.2%) | 19 (52.8%) | 38 (46.9%) | 1 |
| Yes | 10 (22.2%) | 10 (27.8%) | 20 (24.7%) |  |
| Missing | 16 (35.6%) | 7 (19.4%) | 23 (28.4%) |  |
| **Sex** |  |  |  |  |
| Male | 25 (55.6%) | 23 (63.9%) | 48 (59.3%) | 0.595 |
| Female | 20 (44.4%) | 13 (36.1%) | 33 (40.7%) |  |
| **ECOG performance status** |  |  |  |  |
| 0 | 19 (42.2%) | 23 (63.9%) | 42 (51.9%) | 0.094 |
| 1 | 18 (40.0%) | 11 (30.6%) | 29 (35.8%) |  |
| ≥2 | 8 (17.8%) | 2 (5.6%) | 10 (12.3%) |  |

BRAFi/MEKi: Treatment with BRAF/MEK inhibitors. ECOG: Eastern Cooperative Oncology Group. IFNγ: Interferon-γ. Statistical test for categorical data: chi²-test. Statistical test for numerical data: Unequal variances t-test (Welch’s t-test).

**Table 2: Tumor characteristics grouped by response to ICI.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Non-Responders (N=45)** | **Responders (N=36)** | **Overall**  **(N=81)** | **P-value** |
| **BRAF-status** |  |  |  |  |
| Wildtype | 17 (37.8%) | 23 (63.9%) | 40 (49.4%) | 0.0536 |
| Mutated | 26 (57.8%) | 13 (36.1%) | 39 (48.1%) |  |
| Missing | 2 (4.4%) | 0 (0%) | 2 (2.5%) |  |
| **AJCC stage (8th edition)** |  |  |  |  |
| II | 0 (0%) | 1 (2.8%) | 1 (1.2%) | 0.498 |
| III | 6 (13.3%) | 4 (11.1%) | 10 (12.3%) |  |
| IV | 39 (86.7%) | 28 (77.8%) | 67 (82.7%) |  |
| Missing | 0 (0%) | 3 (8.3%) | 3 (3.7%) |  |
| **Brain metastasis** |  |  |  |  |
| No | 16 (35.6%) | 18 (50.0%) | 34 (42.0%) | 0.62 |
| Yes | 10 (22.2%) | 7 (19.4%) | 17 (21.0%) |  |
| Missing | 19 (42.2%) | 11 (30.6%) | 30 (37.0%) |  |
| **Subtype** |  |  |  |  |
| Cutaneous | 40 (88.9%) | 31 (86.1%) | 71 (87.7%) | 0.807 |
| Mucosal | 2 (4.4%) | 3 (8.3%) | 5 (6.2%) |  |
| Missing | 3 (6.7%) | 2 (5.6%) | 5 (6.2%) |  |

AJCC staging (8th edition): American Joint Committee of Cancer staging system for melanoma. Statistical test for categorical data: chi²-test. Statistical test for numerical data: Unequal variances t-test (Welch’s t-test).